Compare · EW vs ZY
EW vs ZY
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Zymergen Inc. (ZY): market cap, price performance, sector, and recent activity on the wire.
Summary
- EW operates in Health Care, while ZY operates in Industrials - the two are in different parts of the market.
- EW is the larger of the two at $65.47B, about 134.0x ZY ($488.5M).
- EW has hit the wire 5 times in the past 4 weeks while ZY has been quiet.
- EW has more recent analyst coverage (25 ratings vs 13 for ZY).
- Company
- Edwards Lifesciences Corporation
- Zymergen Inc.
- Price
- $84.16+5.54%
- $2.44+2.10%
- Market cap
- $65.47B
- $488.5M
- 1M return
- +1.83%
- -
- 1Y return
- +11.37%
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 13
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Zymergen Inc.
Zymergen Inc. designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe. The company has a platform that treats the genome as a search space, to identify genetic changes that improve the economics for its customers' bio-based products for a range of industries, including chemicals and materials, agriculture, and pharmaceuticals. Zymergen's platform is used to discover novel molecules used to enable unique material properties. The company was incorporated in 2013 and is based in Emeryville, California.
Latest EW
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Lippis Daniel J.
- SEC Form 4 filed by Bobo Donald E Jr
- Edwards Lifesciences upgraded by Wolfe Research with a new price target
- Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
- Amendment: SEC Form SCHEDULE 13G/A filed by Edwards Lifesciences Corporation
- SEC Form DEFA14A filed by Edwards Lifesciences Corporation
Latest ZY
- SEC Form 15-12G filed by Zymergen Inc.
- SEC Form EFFECT filed by Zymergen Inc.
- SEC Form SC 13G/A filed by Zymergen Inc. (Amendment)
- SEC Form 4: Svf Excalibur (Cayman) Ltd disposed of 26,614,219 shares
- SEC Form 4: Flatley Jay T returned 144,789 shares to the company, closing all direct ownership in the company
- SEC Form 4: Chu Steven returned 50,000 shares to the company, closing all direct ownership in the company
- SEC Form 4: Peterson Sandra E returned 119,119 shares to the company, closing all direct ownership in the company
- SEC Form 4: Murdoch Travis returned 79,697 shares to the company, closing all direct ownership in the company
- SEC Form 4: Gorjanc Christine Marie returned 50,000 shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Sharma Rohit